Rosenfield R L, Barnes R B, Ehrmann D A
Department of Pediatrics, University of Chicago, Pritzker School of Medicine, Illinois 60637.
J Clin Endocrinol Metab. 1994 Dec;79(6):1686-92. doi: 10.1210/jcem.79.6.7989476.
Plasma 17-hydroxyprogesterone (17PROG) hyperresponsiveness to GnRH agonist (nafarelin) testing is typical of polycystic ovary syndrome and other functional ovarian hyperandrogenism (FOH) that does not meet customary criteria for the diagnosis of polycystic ovary syndrome. We have postulated that this results from abnormal regulation of androgen secretion. Whether this dysregulation is the result of a normal physiological response to ovarian hyperstimulation or escape from down-regulation of steroidogenesis is unknown. To distinguish between these possibilities, we have analyzed the ovarian steroid responses to nafarelin for the apparent efficiency of the steroidogenic steps and the apparent dose-response relationships between blood LH and steroid levels. We compared normal women (n = 18) with three groups of hyperandrogenic women (n = 15-19/group): patients with 17PROG hyperresponsiveness with or without elevated LH levels (type 1 and type 2 FOH, respectively) and patients with normal 17PROG responses to nafarelin (nafarelin negative). Subjects were pretreated with dexamethasone to suppress coincidental adrenal contributions to plasma steroid levels. The pattern of steroid secretion was similarly abnormal in both types of FOH, with the high LH group having generally more severe abnormalities in the levels of steroid intermediates. Baseline 17PROG and 17-hydroxypregnenolone and the ratio of 17PROG to androstenedione (AD) were increased (P < 0.05). In addition, the apparent slope of the 17PROG response to LH was significantly increased. Baseline levels of both AD and dehydroepiandrosterone and the AD response to nafarelin were increased, yet the ratio of peak minus baseline (delta) AD/delta 17PROG (another index of 17,20-lyase activity) was subnormal in FOH. The apparent slope of the testosterone (T) response to LH was significantly increased, and indexes of aromatase activity [estradiol (E2)/T and delta estradiol/delta T] were significantly decreased. Nafarelin stimulated plasma E2 in all groups to rise along an apparently similar LH-E2 dose-response slope. We interpret these results as indicating that FOH patients have generalized overactivity of thecal steroidogenesis, but nevertheless compensate so as to maintain a normal dose-response relationship between blood levels of LH and E2. FOH patients, whether they have LH excess or not, seen to form excessive 17PROG and incompletely dampen (down-regulate) thecal cell 17PROG, AD, and T secretion in response to LH stimulation. 17PROG hyperresponsiveness to nafarelin seems to be prominent both because it is formed in excess and because 17,20-lyase efficiency is rate limiting. The T elevation seems to arise mainly from overactive steroidogenesis, but also partly from an additional functional decrease in aromatase efficiency, which is secondary to negative feedback by the substrate-driven tendency toward estrogen excess.(ABSTRACT TRUNCATED AT 400 WORDS)
血浆17 - 羟孕酮(17PROG)对促性腺激素释放激素激动剂(那法瑞林)检测的高反应性是多囊卵巢综合征及其他功能性卵巢雄激素过多症(FOH)的典型表现,后者不符合多囊卵巢综合征的常规诊断标准。我们推测这是雄激素分泌异常调节所致。这种失调是对卵巢过度刺激的正常生理反应,还是甾体激素生成下调逃逸的结果尚不清楚。为区分这些可能性,我们分析了那法瑞林刺激后的卵巢甾体反应,以了解甾体生成步骤的表观效率以及血LH与甾体水平之间的表观剂量反应关系。我们将正常女性(n = 18)与三组高雄激素女性(每组n = 15 - 19)进行了比较:17PROG高反应性且LH水平升高或未升高的患者(分别为1型和2型FOH)以及对那法瑞林17PROG反应正常(那法瑞林阴性)的患者。受试者先用地塞米松预处理,以抑制肾上腺对血浆甾体水平的巧合性贡献。两种类型的FOH中甾体分泌模式同样异常,LH水平高的组在甾体中间体水平上通常有更严重的异常。基线17PROG、17 - 羟孕烯醇酮以及17PROG与雄烯二酮(AD)的比值升高(P < 0.05)。此外,17PROG对LH反应的表观斜率显著增加。AD和脱氢表雄酮的基线水平以及AD对那法瑞林的反应均升高,但在FOH中,峰减去基线(delta)AD/delta 17PROG(17,20 - 裂解酶活性的另一个指标)低于正常水平。睾酮(T)对LH反应的表观斜率显著增加,芳香化酶活性指标[雌二醇(E2)/T和delta雌二醇/delta T]显著降低。那法瑞林刺激后,所有组的血浆E2均沿着明显相似的LH - E2剂量反应斜率升高。我们将这些结果解释为表明FOH患者存在卵泡膜细胞甾体生成普遍亢进,但仍能进行代偿,从而维持血LH水平与E2之间的正常剂量反应关系。无论是否存在LH过量,FOH患者似乎都会生成过量的17PROG,并且在LH刺激下,卵泡膜细胞17PROG、AD和T的分泌不能完全被抑制(下调)。17PROG对那法瑞林的高反应性似乎很突出,这既是因为它生成过多,也是因为17,2